A micro-RNA expression signature for human NAFLD progression
- PMID: 26874844
- PMCID: PMC4983265
- DOI: 10.1007/s00535-016-1178-0
A micro-RNA expression signature for human NAFLD progression
Abstract
Background: The spectrum of nonalcoholic fatty liver disease (NAFLD) describes disease conditions deteriorating from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) to cirrhosis (CIR) to hepatocellular carcinoma (HCC). From a molecular and biochemical perspective, our understanding of the etiology of this disease is limited by the broad spectrum of disease presentations, the lack of a thorough understanding of the factors contributing to disease susceptibility, and ethical concerns related to repeat sampling of the liver. To better understand the factors associated with disease progression, we investigated by next-generation RNA sequencing the altered expression of microRNAs (miRNAs) in liver biopsies of class III obese subjects (body mass index ≥40 kg/m(2)) biopsied at the time of elective bariatric surgery.
Methods: Clinical characteristics and unbiased RNA expression profiles for 233 miRs, 313 transfer RNAs (tRNAs), and 392 miscellaneous small RNAs (snoRNAs, snRNAs, rRNAs) were compared among 36 liver biopsy specimens stratified by disease severity.
Results: The abundances of 3 miRNAs that were found to be differentially regulated (miR-301a-3p and miR-34a-5p increased and miR-375 decreased) with disease progression were validated by RT-PCR. No tRNAs or miscellaneous RNAs were found to be associated with disease severity. Similar patterns of increased miR-301a and decreased miR-375 expression were observed in 134 hepatocellular carcinoma (HCC) samples deposited in The Cancer Genome Atlas (TCGA).
Conclusions: Our analytical results suggest that NAFLD severity is associated with a specific pattern of altered hepatic microRNA expression that may drive the hallmark of this disorder: altered lipid and carbohydrate metabolism. The three identified miRNAs can potentially be used as biomarkers to access the severity of NAFLD. The persistence of this miRNA expression pattern in an external validation cohort of HCC samples suggests that specific microRNA expression patterns may permit and/or sustain NAFLD development to HCC.
Keywords: HCC; Hepatocellular carcinoma; NAFLD; NASH; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; miRNA.
Figures

Similar articles
-
MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.BMC Cancer. 2016 Jan 5;16:3. doi: 10.1186/s12885-015-2007-1. BMC Cancer. 2016. PMID: 26728044 Free PMC article.
-
Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Gene. 2020 Jun 5;742:144549. doi: 10.1016/j.gene.2020.144549. Epub 2020 Mar 14. Gene. 2020. PMID: 32184169
-
Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.Hepatol Int. 2016 Jul;10(4):647-56. doi: 10.1007/s12072-016-9729-2. Epub 2016 Apr 13. Hepatol Int. 2016. PMID: 27074850
-
MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.Mol Metab. 2022 Nov;65:101581. doi: 10.1016/j.molmet.2022.101581. Epub 2022 Aug 23. Mol Metab. 2022. PMID: 36028120 Free PMC article. Review.
-
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539. World J Gastroenterol. 2014. PMID: 25400438 Free PMC article. Review.
Cited by
-
Higher plain water intake is related to lower newly diagnosed nonalcoholic fatty liver disease risk: a population-based study.Eur J Clin Nutr. 2021 Dec;75(12):1801-1808. doi: 10.1038/s41430-021-00891-9. Epub 2021 Apr 9. Eur J Clin Nutr. 2021. PMID: 33837275
-
MicroRNA-34a Mediates High-Fat-Induced Hepatic Insulin Resistance by Targeting ENO3.Nutrients. 2023 Oct 31;15(21):4616. doi: 10.3390/nu15214616. Nutrients. 2023. PMID: 37960269 Free PMC article.
-
Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics.Nutrients. 2024 Sep 11;16(18):3061. doi: 10.3390/nu16183061. Nutrients. 2024. PMID: 39339660 Free PMC article. Review.
-
Plasma Extracellular Vesicle-derived MicroRNA Associated with Human Alpha-1 Antitrypsin Deficiency-mediated Liver Disease.J Clin Transl Hepatol. 2025 Feb 28;13(2):118-129. doi: 10.14218/JCTH.2024.00253. Epub 2024 Nov 19. J Clin Transl Hepatol. 2025. PMID: 39917464 Free PMC article.
-
Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease.Metabolites. 2023 Oct 29;13(11):1115. doi: 10.3390/metabo13111115. Metabolites. 2023. PMID: 37999211 Free PMC article. Review.
References
-
- Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2004;2(12):1048–58. - PubMed
-
- Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23. - PubMed
-
- Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865–73. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical